CoChat

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Duloxetine for the Treatment of Pain in Patients with Multiple Sclerosis

Vollmer, Timothy L., Robinson, Michael J., Risser, Richard C., Malcolm, Sandra K. · 2014 · Pain Practice
Cited by 65

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Patients with multiple sclerosis (MS) often report neuropathic pain (NP‐MS). The purpose of this study was to assess the efficacy and tolerability of duloxetine as treatment for NP‐MS. Methods: In this study, 239 adults with NP‐MS (duloxetine = 118, placebo = 121) were randomized to duloxetine 60 mg (30 mg for 1 week, then 60 mg for 5 weeks) or placebo once daily for a 6‐week acute therapy phase, followed by a 12‐week open‐label extension phase (duloxetine 30 to 120 mg/day). Eligible patients had MS for ≥ 1 year and a score ≥ 4 on daily average pain intensity (API) ratings for ≥ 4 of 7 days immediately before randomization. Patients rated API daily on an 11‐point numeric scale (0 [no pain] to 10 [worst possible pain]) in an electronic diary. The primary efficacy measure, change in weekly API ratings, was analyzed longitudinally with a mixed‐model repeated‐measures analysis. Completion, reasons for discontinuation, and treatment‐emergent adverse event incidence were compared by Fisher's exact test. Results: Duloxetine‐treated patients had statistically greater mean improvement in API vs. placebo at Week 6 (−1.83 vs. −1.07, P = 0.001). Treatment completion did not significantly differ between groups. Discontinuation due to adverse events was statistically greater for duloxetine vs. placebo (13.6% vs. 4.1%, P = 0.012). Decreased appetite was reported significantly more often by duloxetine‐treated patients (5.9% vs. 0%, P = 0.007). Conclusions: This study found analgesic efficacy of duloxetine for NP‐MS. Duloxetine is not approved for treatment of this condition. The duloxetine safety profile of this study was consistent with the known profile in other patient populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/papr.12127

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 65

Metadata

Authors
Vollmer, T. L., Robinson, M. J., Risser, R. C., & Malcolm, S. K.
Venue
Pain Practice
Publisher
Wiley
Published
2013-10-24
Volume
14
Issue
8
Pages
732-744
ISSN
  • 1530-7085 (ISSN-L)
  • 1533-2500
OpenAlex
W1988039811
Cited by
65
References
5
FWCI
2.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.